跳轉至內容
Merck
全部照片(1)

重要文件

AB2910

Sigma-Aldrich

Anti-Mcl-1 Antibody

serum, Chemicon®

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物源

rabbit

品質等級

抗體表格

serum

抗體產品種類

primary antibodies

無性繁殖

polyclonal

物種活性

human

製造商/商標名

Chemicon®

技術

immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable

UniProt登錄號

運輸包裝

dry ice

目標翻譯後修改

unmodified

基因資訊

human ... MCL1(4170)

特異性

Recognizes Human Mcl-1. Not reactive with other members of the Bcl-2 family, as verified by immunoblot.

免疫原

Synthetic peptide corresponding to amino acids 121-139 of human Mcl-1.

應用

Immunoblot 1:2,000

Immunoprecipitation. Precipitates a 37-39 kDa protein, which appears as a doublet in some cells.

Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)

The following tissues/cells can serve as positive controls: tonsil, tonsillar B cells, B-cell lines Reh, Daudi, and Karpas 422.

Optimal working dilutions for AB2910 must be determined by end user.
Research Category
Apoptosis & Cancer
Research Sub Category
BCL2 & Inhibition
This Anti-Mcl-1 Antibody is validated for use in IP, WB, IH(P) for the detection of Mcl-1.

外觀

Liquid antiserum.

儲存和穩定性

Store at -20°C for up to 12 months in undiluted aliquots. Avoid repeated freeze-thaw cycles.

法律資訊

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 1


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Yixiang Li et al.
Theranostics, 10(17), 7656-7670 (2020-07-21)
Prostate cancer is the second leading cause of cancer-related death in the United States. As a first line treatment for hormone-refractory prostate cancer, docetaxel (DTX) treatment leads to suboptimal effect since almost all patients eventually develop DTX resistance. In this
Nicole M Smith et al.
Journal of neuroinflammation, 15(1), 201-201 (2018-07-10)
Following injury to the central nervous system, increased microglia, secretion of pro- and anti-inflammatory cytokines, and altered blood-brain barrier permeability, a hallmark of degeneration, are observed at and immediately adjacent to the injury site. However, few studies investigate how regions

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務